Second, refining therapeutic strategies, such as developing dual-targeted approaches that simultaneously inhibit GM-CSF and other pro-inflammatory cytokines (e.g., IL-17 or IFN-γ) implicated in MS pathogenesis. This evidence concerns the gene IFNG and myeloid sarcoma.